AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23203140 — intervention group
Group type: COMPARATOR
Intervention: 15 g milk protein
Number of subjects: 180
Study 21044715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nijmegen Falls Prevention Program (NFPP) for persons with osteoporosis (5.5 weeks)
Number of subjects: 96
Study 21044715 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 96
Study 19072879 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 60
Study 19072879 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 60
Study 16365182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive surveillance strategy (including clinical evaluation, serum carcinoembryonic antigen monitoring, abdominal CT or ultrasonography, chest radiograph, and colonoscopy)
Number of subjects: 259
Study 16365182 — intervention group
Group type: COMPARATOR
Intervention: Simple surveillance strategy (clinical evaluation and serum carcinoembryonic antigen monitoring)
Number of subjects: 259
Study 14508032 — intervention group
Group type: EXPERIMENTAL
Intervention: EXP
Number of subjects: 63
Study 14508032 — intervention group
Group type: COMPARATOR
Intervention: CTL
Number of subjects: 63
Study 10807441 — intervention group
Group type: COMPARATOR
Intervention: No postoperative pacing
Number of subjects: 154
Study 10807441 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial pacing (RAP)
Number of subjects: 154
Study 10807441 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial pacing (LAP)
Number of subjects: 154
Study 10807441 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatrial pacing (BAP)
Number of subjects: 154
Study 10807441 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative atrial pacing (any pacing strategy)
Number of subjects: 154
Study 8836267 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam gel 15gm
Number of subjects: 42
Study 8836267 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic field block with 20 ml of 0.375% bupivacaine
Number of subjects: 42
Study 8836267 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 42
Study 1349676 — intervention group
Group type: EXPERIMENTAL
Intervention: olsalazine (Dipentum; 1.0 g daily)
Number of subjects: 100
Study 1349676 — intervention group
Group type: COMPARATOR
Intervention: mesalazine (Asacol, with Eudragit‐S coating; 1.2 g daily)
Number of subjects: 100
Study 1349676 — intervention group
Group type: EXPERIMENTAL
Intervention: olsalazine
Number of subjects: 100
Study 1349676 — intervention group
Group type: COMPARATOR
Intervention: mesalazine
Number of subjects: 100
Study 31910201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 24
Study 31910201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30992150 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg QD
Number of subjects: 860
Study 30992150 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg BID
Number of subjects: 860
Study 30992150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 860
Study 30992150 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix (both dosages)
Number of subjects: 860
Study 28315283 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing Rehabilitation Protocol (SRP) including neuromuscular electrical stimulation, thermal tactile stimulation, and hyolaryngeal mobilization
Number of subjects: 24
Study 28315283 — intervention group
Group type: COMPARATOR
Intervention: Nonnutritive stimulations (Control)
Number of subjects: 24
Study 25690438 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for general practitioners and nursing home staff
Number of subjects: 239
Study 25690438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 239
Study 25688512 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus in combination with octreotide LAR and metformin
Number of subjects: 43
Study 22390264 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who were given the opportunity to misattribute arousal (experimental group)
Number of subjects: 40
Study 22390264 — intervention group
Group type: COMPARATOR
Intervention: Participants who were not given any misattribution cues (control group)
Number of subjects: 40
Study 22390264 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who did not misattribute their arousal to the placebo beverage
Number of subjects: 40
Study 19205290 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of fluticasone propionate at 200 microg/d for 4 weeks
Number of subjects: 23
Study 19205290 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovator formulation of fluticasone propionate at 200 microg/d for 4 weeks
Number of subjects: 23
Study 19205290 — intervention group
Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 23
Study 17650355 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP bottle
Number of subjects: 20
Study 17650355 — intervention group
Group type: COMPARATOR
Intervention: PEP mask
Number of subjects: 20
Study 15635132 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 86
Study 15635132 — intervention group
Group type: COMPARATOR
Intervention: Midazolam/Fentanyl
Number of subjects: 86
Study 12396273 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg (14)C‐labelled emedastine difumarate (mass balance study)
Number of subjects: 24
Study 12396273 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oral emedastine difumarate b.i.d. or 4 mg o.d. for 7 consecutive days (single- and multiple-dose pharmacokinetic study)
Number of subjects: 24
Study 10535240 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 71
Study 10535240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)
Number of subjects: 71
Study 10535240 — intervention group
Group type: COMPARATOR
Intervention: Wait list (WL)
Number of subjects: 71
Study 7775859 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4 g/day)
Number of subjects: 20
Study 7775859 — intervention group
Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 20
Study 7775859 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil fatty acids in vitro
Number of subjects: 20
Study 2182581 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI/WBH (Whole Body Hyperthermia at 41.8 degrees C, initiated 10 min after TBI)
Number of subjects: 18
Study 2182581 — intervention group
Group type: COMPARATOR
Intervention: TBI/LON (Lonidamine 420 mg/m2 orally daily)
Number of subjects: 18
Study 121884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nivimedone (200 mg thrice daily)
Number of subjects: 24
Study 121884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31757641 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact intervention
Number of subjects: 39
Study 31757641 — intervention group
Group type: COMPARATOR
Intervention: Education intervention
Number of subjects: 39
Study 29199916 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent Medical Evaluation (IME)
Number of subjects: 9
Study 29199916 — intervention group
Group type: EXPERIMENTAL
Intervention: IME working conditions
Number of subjects: 9
Study 29199916 — intervention group
Group type: COMPARATOR
Intervention: General Practitioners (GPs)
Number of subjects: 9
Study 26139736 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 94
Study 26139736 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 94
Study 23951335 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase advance (21h cycle)
Number of subjects: 13
Study 23951335 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase delay (27h cycle)
Number of subjects: 13
Study 23951335 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment (both phase advance and phase delay)
Number of subjects: 13
Study 23951335 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter REM sleep during the second part of the night
Number of subjects: 13
Study 21294047 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic Action Test (planning behaviours and planning time)
Number of subjects: 48
Study 21294047 — intervention group
Group type: COMPARATOR
Intervention: Naturalistic Action Test
Number of subjects: 48
Study 19174452 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alpha (EPOalpha) 150 UI/kg/TIW s.c. (arm 1)
Number of subjects: 218
Study 19174452 — intervention group
Group type: COMPARATOR
Intervention: No EPOalpha (arm 2)
Number of subjects: 218
Study 19174452 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alpha (EPOalpha)
Number of subjects: 218
Study 19174452 — intervention group
Group type: COMPARATOR
Intervention: No EPOalpha
Number of subjects: 218
Study 17101711 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg vitamin K1 intramuscularly (control)
Number of subjects: 0
Study 17101711 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg vitamin K1 intramuscularly
Number of subjects: 0
Study 17101711 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg vitamin K1 intravenously
Number of subjects: 0
Study 17101711 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg vitamin K1 intramuscularly
Number of subjects: 0
Study 15598026 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed release glucosamine sulfate (TimeOsamine) 1,000 mg (2 x 500 mg)
Number of subjects: 12
Study 15598026 — intervention group
Group type: COMPARATOR
Intervention: Powder-filled glucosamine sulfate formulation 1,500 mg (3 x 500 mg)
Number of subjects: 12
Study 11499735 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg/day)
Number of subjects: 91
Study 11499735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 11499735 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified (high-dose angiotensin-converting enzyme inhibitors and beta-blocker therapy)
Number of subjects: 91
Study 9269267 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-salicylate gel (1.5 g) applied twice daily for four weeks
Number of subjects: 116
Study 9269267 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (1.5 g) applied twice daily for four weeks
Number of subjects: 116
Study 8387151 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (2 mg E2V and 1 mg CPA)
Number of subjects: 0
Study 8387151 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (1 mg E2V and 0.5 mg CPA)
Number of subjects: 0
Study 8387151 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C (2 mg E2V and 2 mg CPA)
Number of subjects: 0
Study 2820329 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 40
Study 2820329 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene and hydrochlorothiazide (Dyazide)
Number of subjects: 40
Study 2820329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29300214 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-s static stretch (5S)
Number of subjects: 20
Study 29300214 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-s static stretch (30S)
Number of subjects: 20
Study 29300214 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-repetition dynamic stretch (DYN)
Number of subjects: 20
Study 29300214 — intervention group
Group type: COMPARATOR
Intervention: No-stretch (NS)
Number of subjects: 20
Study 27924521 — intervention group
Group type: EXPERIMENTAL
Intervention: LISA
Number of subjects: 44
Study 27924521 — intervention group
Group type: EXPERIMENTAL
Intervention: INSURE
Number of subjects: 44
Study 25338765 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 85
Study 25338765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 23543732 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (75 mcg)
Number of subjects: 98
Study 23543732 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (4 mg)
Number of subjects: 98
Study 20459404 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day, n=48)
Number of subjects: 63
Study 20459404 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (n=15)
Number of subjects: 63
Study 18514166 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodromal subjects and unmedicated first-episode schizophrenia patients
Number of subjects: 54
Study 18514166 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients treated with risperidone
Number of subjects: 54
Study 18514166 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 54
Study 18514166 — intervention group
Group type: COMPARATOR
Intervention: Prodromal subjects and schizophrenia patients
Number of subjects: 54
Study 16160627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (3 mg/kg daily for 6 months)
Number of subjects: 12
Study 16160627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11803237 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg) in severity stratum 1 (MMSE >23)
Number of subjects: 52
Study 11803237 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg) in severity stratum 2 (MMSE <24)
Number of subjects: 52
Study 11803237 — intervention group
Group type: COMPARATOR
Intervention: Placebo in severity stratum 1 (MMSE >23)
Number of subjects: 52
Study 11803237 — intervention group
Group type: COMPARATOR
Intervention: Placebo in severity stratum 2 (MMSE <24)
Number of subjects: 52
Study 11803237 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg) in patients with very mild to mild cognitive impairment
Number of subjects: 52
Study 11803237 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg) in patients with more severe dementia
Number of subjects: 52
Study 10598610 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and postoperative atenolol
Number of subjects: 63
Study 10598610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative atenolol
Number of subjects: 63
Study 10598610 — intervention group
Group type: COMPARATOR
Intervention: No atenolol
Number of subjects: 63
Study 7863761 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal laminar flow ventilation and conventional clothes (cotton shirts and trousers)
Number of subjects: 90
Study 7863761 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal laminar flow ventilation and occlusive garments (Klinidress)
Number of subjects: 90
Study 7863761 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation and occlusive garments
Number of subjects: 90
Study 7863761 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal laminar flow ventilation with occlusive clothes during knee arthroplasty
Number of subjects: 90
Study 7863761 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal laminar flow ventilation during hip arthroplasty
Number of subjects: 90
Study 1722989 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids
Number of subjects: 50
Study 1722989 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid treatment
Number of subjects: 50
Study 6175494 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenon (3 x 150 mg daily)
Number of subjects: 15
Study 6175494 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (3 x 20 mg daily)
Number of subjects: 15
Study 6175494 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenon plus Propranolol
Number of subjects: 15
Study 6175494 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenon alone
Number of subjects: 15
Study 6175494 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 15
Study 29904203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprayed-dried colostrum-based (CR; n = 8)
Number of subjects: 17
Study 29904203 — intervention group
Group type: COMPARATOR
Intervention: Plasma-based colostrum replacement product (PR; n = 9)
Number of subjects: 17
Study 26821116 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt smoothies alone (YS)
Number of subjects: 30
Study 26821116 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoothies with BB-12 added before yogurt fermentation (PRE)
Number of subjects: 30
Study 26821116 — intervention group
Group type: EXPERIMENTAL
Intervention: BB-12 capsule (CAP)
Number of subjects: 30
Study 26821116 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoothies with BB-12 added after yogurt fermentation (POST)
Number of subjects: 30
Study 24557111 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized PEEP (10 ± 2 cm·H2O)
Number of subjects: 30
Study 24557111 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized PEEP
Number of subjects: 30
Study 24557111 — intervention group
Group type: COMPARATOR
Intervention: Standardized PEEP (5 cm·H2O)
Number of subjects: 30
Study 22763899 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with levobupivacaine 0.375% 20 mL
Number of subjects: 65
Study 22763899 — intervention group
Group type: COMPARATOR
Intervention: Sham block with 20 mL 0.9% saline (Control)
Number of subjects: 65
Study 20388624 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 45
Study 20388624 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% gelatin
Number of subjects: 45
Study 20388624 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 45
Study 20388624 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 45
Study 20388624 — intervention group
Group type: EXPERIMENTAL
Intervention: gelatin
Number of subjects: 45
Study 20388624 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study 17894937 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 174
Study 17894937 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 174
Study 15921806 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1321
Study 15921806 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1321
Study 15921806 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (stayed on the same drug)
Number of subjects: 1321
Study 15921806 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (stayed on the same drug)
Number of subjects: 1321
Study 12067005 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% articaine with epinephrine 1:200,000
Number of subjects: 82
Study 12067005 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine and 2% lidocaine with epinephrine 1:200,000
Number of subjects: 82
Study 10653861 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 228
Study 10653861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 228
Study 10653861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 8862164 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced HIV Prevention Counseling (4 sessions)
Number of subjects: 0
Study 8862164 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV Prevention Counseling (2 sessions)
Number of subjects: 0
Study 8862164 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV Education (2 sessions)
Number of subjects: 0
Study 1538559 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 593
Study 1538559 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 593
Study 1538559 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diet
Number of subjects: 593
Study 1538559 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium/high potassium diet
Number of subjects: 593
Study 6467282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 500 mg
Number of subjects: 0
Study 6467282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 1 gm
Number of subjects: 0
Study 6467282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 2 gm
Number of subjects: 0
Study 6467282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin 2 gm
Number of subjects: 0
Study 6467282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephapirin 1 gm
Number of subjects: 0
Study 6467282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin 1 gm
Number of subjects: 0
Study 6467282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole 0.5 gm
Number of subjects: 0
Study 31779922 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA treatment
Number of subjects: 1756
Study 31779922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1756
Study 29702283 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual Immunotherapy (SLIT)
Number of subjects: 26
Study 29702283 — intervention group
Group type: COMPARATOR
Intervention: Traditional anti-allergic medications (Control)
Number of subjects: 26
Study 26992569 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT+ITS (intensive text-message and e-mail support)
Number of subjects: 60
Study 26992569 — intervention group
Group type: COMPARATOR
Intervention: CBT+MTS (minimal text-message support)
Number of subjects: 60
Study 25311734 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunlight-derived ultraviolet radiation (UVR) exposure over 6 months
Number of subjects: 248
Study 22991405 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic PDE5I (sildenafil® 20 mg tid for 12 weeks followed by 60 mg tid for 12 weeks)
Number of subjects: 0
Study 22991405 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic PDE5I (sildenafil®)
Number of subjects: 0
Study 20415618 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic nurse disease management program (DM) including educational materials, lifestyle and diet counseling, and home BP monitor
Number of subjects: 485
Study 20415618 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic nurse disease management program (DM)
Number of subjects: 485
Study 20415618 — intervention group
Group type: COMPARATOR
Intervention: Home BP monitor alone
Number of subjects: 485
Study 17321104 — intervention group
Group type: EXPERIMENTAL
Intervention: High social anxiety individuals
Number of subjects: 0
Study 17321104 — intervention group
Group type: COMPARATOR
Intervention: Low social anxiety individuals
Number of subjects: 0
Study 17321104 — intervention group
Group type: COMPARATOR
Intervention: Distraction coping
Number of subjects: 0